In a large, prospective cohort of women, those with LDL-c <70 mg/dL and potentially those with LDL-c ≥160 mg/dL and those with low TG, showed a higher risk of hemorrhagic stroke.
The PALM registry reveals that 27% of adults who were eligible for statin therapy, did not use it. In almost 60%, this was because they were never offered a statin. Others discontinued, or declined use
Safety of bempedoic acid was studied over a 1-year period in the CLEAR Harmony trial, which enrolled high CV risk patients.
Mendelian randomization study provides genetic validation for ATP citrate lyase as target (of bempedoic acid) in LDL-c lowering to reduce CV risk, to a similar extent as inhibiting HMGCR with a statin.
Among US adults, higher consumption of dietary cholesterol or eggs was significantly associated with higher risk of incident CVD and all-cause mortality in a dose-response manner.
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.
Observational and genetic analyses found a causal positive association of LDL-c with ischemic stroke and a causal negative association with ICH in a Chinese population. Using randomized trial data, a net benefit for the prevention of overall stroke with lowering LDL-c was shown.
CME accredited course focussed on PCSK9 inhibitors as novel strategy to reduce LDL-C. Member registration (free) is needed to enroll in this course
A prespecified analysis of the ODYSSEY OUTCOMES trial showed a higher incidence of MACE and death in ACS patients with polyvascular disease and alirocumab treatment resulted in a large absolute benefit in these patients.
ACC 2019 The results of the CLEAR WIsdom trial are summarized by prof Goldberg, with lowering of LDL-c in response to bempedoic acid vs placebo as most important finding.
ACC 2019 Results of the CLEAR Wisdom trial showed that bempedoic acid lowered LDL-c in high CV risk patients with elevated LDL-c levels who are on maximally tolerated statin and/or other lipid-modifying therapies.
Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.